Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
FATE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Fate Therapeutics, Inc.NASDAQ: FATE
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $1.3M fell 20.3% year over year, ahead of the -52.6% change in trailing-twelve-month revenue. Sequentially, it fell 5.1% from the prior quarter. Over 3 fiscal years it compounded at -59.0% a year.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $5.71M (-14.1%) for the fiscal year ending Dec 2026, a step up from the -51.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.3M-5.1% QoQ
- Last fiscal yearDec 2025
- $6.65M-51.2% YoY
- LTMMar 2026
- $6.32M-52.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.3% | -29.7% | -9.5 pp |
| 1 year | -51.2% | -14.1% | +37.2 pp |
| 3-year CAGR | -59.0% | -22.5% | +36.5 pp |
| 5-year CAGR | +73.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 6.65M USD
- Year-over-year change
- -51.2%
- 4-year CAGR
- -41.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.65M | -51.2% |
| FY2024 | 2024-12-31 | 13.63M | -78.5% |
| FY2023 | 2023-12-31 | 63.53M | -34.0% |
| FY2022 | 2022-12-31 | 96.3M | +72.4% |
| FY2021 | 2021-12-31 | 55.85M | — |
Revenue vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -52.6% is the 2nd highest of 5, against a peer median of -89.6%.
- Over three fiscal years its annual growth of -59.0% compares with a peer median of -63.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $18.42M USD | -79.2% | -46.0% | |
| LTM Mar 2026 | $16.72M USD | +138.9% | — | |
| LTM Mar 2026 | $6.32M USD | -52.6% | -59.0% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | CHF 0 CHF | -100.0% | — | |
| LTM Mar 2026 | $0 USD | -100.0% | -81.5% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding FATE) | — | -89.6% | -63.7% | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M |
| Cost of Revenue | 5.85M | 13.76M | 157.19M | 118.53M | 12.9M |
| Gross Profit | 50M | 82.54M | (93.65M) | (104.9M) | (6.26M) |
| Gross Margin | 89.5% | 85.7% | -147.4% | -769.6% | -94.1% |
| Research & Development | 215.52M | 320.45M | 172.6M | 135M | 107.83M |
| Selling, General & Admin | 57.32M | 84.23M | 96.86M | 90.64M | 46.52M |
| Operating Expenses | 266.99M | 390.93M | 96.86M | 105.38M | 141.45M |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| EBITDA | (206.3M) | (267.96M) | (142.65M) | (176.58M) | (127.02M) |
| EBITDA Margin | -369.4% | -278.3% | -224.5% | -1295.4% | -1911.2% |
| Operating Income | (216.99M) | (308.39M) | (190.51M) | (210.28M) | (147.7M) |
| Operating Margin | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Interest Income | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.84M | 26.67M | 29.58M | 24.01M | 11.39M |
| Income Before Tax | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Pre-Tax Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Net Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (Basic) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| EPS (Diluted) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| Weighted Avg Shares | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
| Weighted Avg Shares (Diluted) | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.